In Situ Activatable Nitrobenzene-Cysteine-Copper(II) Nano-complexes for Programmed Photodynamic Cancer Therapy

Jisoo Kang, Hwajun Jeong, Minseok Jeong, Jaehoon Kim, Sungnam Park, Junyang Jung, Jong Min An, Dokyoung Kim

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Photodynamic therapy (PDT) has been used to reduce cancerous and precancerous cells via reactive oxygen species (ROS) generation from photosensitizers. Numerous photosensitizers are available today to treat a variety of diseases, but their therapeutic efficacy is hindered within the tumor microenvironment, and there are safety concerns associated with their non-specific activation. In this work, we disclosed a nano-therapeutic based on in situ activatable nitrobenzene-cysteine-copper(II) nano-complexes (NCCNs) that work within cancer cells. Among the NCCNs, CyP shows outstanding potential as a promising candidate for programmed photodynamic cancer therapy with its unique properties such as (i) bright near-infrared imaging, (ii) chemodynamic therapeutic effect, (iii) photodynamic therapeutic effect (types I and II), and (iv) anti-cancer effect by anti-angiogenesis in early cancer stage under light. Overall, this work opens up exciting possibilities for the development of innovative and effective treatments for cancer, paving the way for future advancements in the clinical medicine field.

Original languageEnglish
Pages (from-to)27587-27600
Number of pages14
JournalJournal of the American Chemical Society
Issue number50
Publication statusPublished - 2023 Dec 20

Bibliographical note

Publisher Copyright:
© 2023 American Chemical Society.

ASJC Scopus subject areas

  • Catalysis
  • General Chemistry
  • Biochemistry
  • Colloid and Surface Chemistry


Dive into the research topics of 'In Situ Activatable Nitrobenzene-Cysteine-Copper(II) Nano-complexes for Programmed Photodynamic Cancer Therapy'. Together they form a unique fingerprint.

Cite this